logo-loader
viewCanntab Therapeutics Ltd

Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm. 

Goldstein discusses how the deal with work and what is it worth to the company. Meanwhile, Latowsky discusses why he is joining the company and what he sees as the big advantages Canntab has over others.

Quick facts: Canntab Therapeutics Ltd

Price: 0.79 CAD

CSE:PILL
Market: CSE
Market Cap: $24.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Jubilee Metals CEO welcomes 54% growth in first half operational earnings

Jubilee Metals Group PLC's (LON:JLP) Leon Coetzer caught up with Proactive London's Andrew Scott after reporting its sixth consecutive six-monthly period of double digit growth - posting a 54% increase in first-half earnings to £12.8mln. The company was also able to boost revenue by 18% to...

17 hours, 2 minutes ago

2 min read